立体定向体部放疗治疗IIA至IIIA期不可手术非小细胞肺癌:一项1期剂量递增试验
这项1期试验研究SBRT治疗大于3 cm不可手术NSCLC的最大耐受剂量。3+3剂量递增设计(A组)显示50 Gy/5次为MTD,因3例发生3级放射性肺炎;在MTD扩展B组(25例)中无4级以上毒性且无3级放射性肺炎,仅2例发生2级放射性肺炎。2年局部失败累积发生率为20.2%,2年总生存率为53%;生物有效剂量<100 Gy与更高的局部失败相关(P=0.006)。
要点
- 50 Gy/5次是SBRT治疗大于3 cm肿瘤的最大耐受剂量。
- B组(25例)无4级以上放疗相关毒性且无3级放射性肺炎,仅2例发生2级放射性肺炎。
- 生物有效剂量<100 Gy与更高的局部失败相关(P=0.006)。
核心结论
- 50 Gy分5次是SBRT治疗大于3 cm肿瘤的最大耐受剂量。
- 即使在较大肿瘤中,较高的生物有效剂量与较少的局部失败相关。
- B组似乎毒性更少,可能归因于省略了化疗。
研究设计与样本
- 采用3+3剂量递增设计(A组)并在最大耐受剂量下扩展(B组)的1期试验。
- 入组不可手术、大于3 cm(T2-4)的非小细胞肺癌患者,允许选择性地照射同侧肺门和单站纵隔淋巴结。
- 初始SBRT剂量为40 Gy分5次,计划递增至50 Gy和60 Gy分5次。
- A组必须接受辅助化疗,B组辅助化疗为可选,但B组无患者接受化疗。
- 主要终点为SBRT相关的急性4级及以上或持续性3级毒性(不良事件通用术语标准4.03版)。
主要发现
- 中位年龄80岁;肿瘤大小大于3 cm且不超过5 cm者20例(59%),大于5 cm者14例(41%)。
- A组(n=9)中3例接受50 Gy治疗的患者发生3级放射性肺炎,由此确定最大耐受剂量。
- 在较大剂量扩展B组(n=25)中,无放疗相关4级及以上毒性,无3级放射性肺炎;仅2例发生2级放射性肺炎。
- 2年局部失败累积发生率为20.2%,远处失败为34.7%,疾病进展为54.4%,2年总生存率为53%。
- 生物有效剂量<100 Gy与更高的局部失败相关(P=0.006);晚期分期和较高的中性粒细胞/淋巴细胞比值与更大的疾病进展相关(均P=0.004)。
关键数值与推荐
- SBRT初始剂量40 Gy分5次,计划递增至50 Gy和60 Gy分5次。
- A组(n=9)中3例接受50 Gy治疗者发生3级放射性肺炎,据此确定最大耐受剂量为50 Gy分5次。
- B组(n=25)中无4级及以上放疗相关毒性,无3级放射性肺炎,2例发生2级放射性肺炎。
- 2年局部失败累积发生率为20.2%,远处失败为34.7%,疾病进展为54.4%,2年总生存率为53%。
- 生物有效剂量<100 Gy与更高的局部失败相关(P=0.006);晚期分期和较高的中性粒细胞/淋巴细胞比值与更大的疾病进展相关(均P=0.004)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Larger tumors are underrepresented in most prospective trials on stereotactic body radiation therapy (SBRT) for inoperable non-small cell lung cancer (NSCLC). We performed this phase 1 trial to specifically study the maximum tolerated dose (MTD) of SBRT for NSCLC >3 cm. METHODS AND MATERIALS: A 3 + 3 dose-escalation design (cohort A) with an expansion cohort at the MTD (cohort B) was used. Patients with inoperable NSCLC >3 cm (T2-4) were eligible. Select ipsilateral hilar and single-station mediastinal nodes were permitted. The initial SBRT dose was 40 Gy in 5 fractions, with planned escalation to 50 and 60 Gy in 5 fractions. Adjuvant chemotherapy was mandatory for cohort A and optional for cohort B, but no patients in cohort B received chemotherapy. The primary endpoint was SBRT-related acute grade (G) 4+ or persistent G3 toxicities (Common Terminology Criteria for Adverse Events version 4.03). Secondary endpoints included local failure (LF), distant metastases, disease progression, and overall survival. RESULTS: The median age was 80 years; tumor size was >3 cm and ≤5 cm in 20 (59%) and >5 cm in 14 patients (41%). In cohort A (n = 9), 3 patients treated to 50 Gy experienced G3 radiation pneumonitis (RP), thus defining the MTD. In the larger dose-expansion cohort B (n = 25), no radiation therapy-related G4+ toxicities and no G3 RP occurred; only 2 patients experienced G2 RP. The 2-year cumulative incidence of LF was 20.2%, distant failure was 34.7%, and disease progression was 54.4%. Two-year overall survival was 53%. A biologically effective dose (BED) <100 Gy was associated with higher LF (P = .006); advanced stage and higher neutrophil/lymphocyte ratio were associated with greater disease progression (both P = .004). CONCLUSIONS: Fifty Gy in 5 fractions is the MTD for SBRT to tumors >3 cm. A higher BED is associated with fewer LFs even in larger tumors. Cohort B appears to have had less toxicity, possibly due to the omission of chemotherapy.
引用
- Rimner A, Gelblum DY, Wu AJ, et al. Stereotactic Body Radiation Therapy for Stage IIA to IIIA Inoperable Non-Small Cell Lung Cancer: A Phase 1 Dose-Escalation Trial. Int J Radiat Oncol Biol Phys. 2023. PMID: 38154510. doi:10.1016/j.ijrobp.2023.12.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。